Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Damon Labs indictments

This article was originally published in The Gray Sheet

Executive Summary

Damon Labs indictments: Justice Department indicts four former executives of Damon Clinical Laboratories on charges that they conspired to defraud Medicare of "over $25 mil.," according to a Jan. 22 release from the Office of the U.S. Attorney General. Charged are Joseph Isola, Beno Kon, William Thurston and Gerald Kullen. The indictment alleges that the four individuals were involved in a scheme while at Damon to defraud Medicare by adding the infrequently ordered serum ferritin test to a commonly ordered panel of blood chemistry tests, and the apolipoproteins test to a coronary risk profile panel. The indictment also charges that Isola, Kon and Thurston manipulated physician practice by dividing a common test panel for end-stage renal disease patients into two separate panels for which samples were taken on different days. In October 1996, Damon pleaded guilty to conspiracy to defraud Medicare and paid criminal and civil fines totaling $119 mil...

You may also be interested in...

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain

Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts